ValuEngine upgraded shares of Kura Oncology (NASDAQ:KURA) from a hold rating to a buy rating in a report published on Wednesday morning.
Several other equities analysts have also recently weighed in on the stock. Cann assumed coverage on shares of Kura Oncology in a research note on Monday. They set a buy rating and a $35.00 price target for the company. HC Wainwright set a $31.00 price target on shares of Kura Oncology and gave the stock a buy rating in a research note on Thursday, November 1st. BidaskClub cut shares of Kura Oncology from a sell rating to a strong sell rating in a research note on Wednesday, October 24th. Cowen reissued a buy rating on shares of Kura Oncology in a report on Monday, October 22nd. Finally, Zacks Investment Research raised Kura Oncology from a sell rating to a buy rating and set a $18.00 price objective for the company in a report on Tuesday, October 16th. One analyst has rated the stock with a sell rating and eight have issued a buy rating to the company. The company has a consensus rating of Buy and an average price target of $27.67.
Shares of KURA traded down $0.06 during mid-day trading on Wednesday, hitting $12.03. 3,626 shares of the company’s stock were exchanged, compared to its average volume of 394,811. The stock has a market capitalization of $439.09 million, a P/E ratio of -7.84 and a beta of 4.39. Kura Oncology has a 52 week low of $10.20 and a 52 week high of $24.02. The company has a quick ratio of 10.22, a current ratio of 14.76 and a debt-to-equity ratio of 0.02.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Voya Investment Management LLC acquired a new stake in shares of Kura Oncology in the 2nd quarter valued at approximately $187,000. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in Kura Oncology during the 2nd quarter valued at $218,000. BB&T Securities LLC acquired a new stake in Kura Oncology during the 2nd quarter valued at $291,000. Bank of America Corp DE lifted its holdings in Kura Oncology by 327.1% during the 2nd quarter. Bank of America Corp DE now owns 17,729 shares of the company’s stock valued at $323,000 after purchasing an additional 13,578 shares during the last quarter. Finally, WINTON GROUP Ltd acquired a new stake in Kura Oncology during the 3rd quarter valued at $325,000. 77.28% of the stock is owned by institutional investors.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Read More: Understanding the different types of bonds
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.